Utilizing circulating tumor cells: Challenges and pitfalls

Current Opinion in Genetics and Development

Volumn 21, Issue 1, 2011, Pages 50-58

  Attard, Gerhardt ^a   de Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; CD45 ANTIGEN; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPITHELIAL CELL ADHESION MOLECULE; IMATINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PREDNISONE; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR ERG; TRASTUZUMAB;

ADVANCED CANCER; CANCER RESISTANCE; CANCER SURVIVAL; CELL COUNT; CELL ISOLATION; CELL SIZE; CELL VIABILITY; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MYELOID LEUKEMIA; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR EMBOLISM;

CELL SURVIVAL; EARLY DETECTION OF CANCER; GENETIC HETEROGENEITY; HUMANS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79551648084     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2010.10.010     Document Type: Review

References (44)

1. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., Schlimok G., Diel I.J., Gerber B., Gebauer G., et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353:793-802.
2. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W.M.M., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
3. de Bono J.S., Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., Doyle G.V., Terstappen L.W.W.M., Pienta K.J., Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14:6302-6309.
4. Cohen S.J., Punt C.J.A., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M., Mitchell E., Miller M.C., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:3213-3221.
5. Danila D.C., Morris M.J., de Bono J.S., Ryan C.J., Denmeade S.R., Smith M.R., Taplin M.-E., Bubley G.J., Kheoh T., Haqq C., et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010, 28:1496-1501.
6. Reid A.H.M., Attard G., Danila D.C., Oommen N.B., Olmos D., Fong P.C., Molife L.R., Hunt J., Messiou C., Parker C., et al. Significant and sustained antitumor activity in post-docetaxel castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010.
7. Attard G., Reid A.H.M., A'Hern R., Parker C., Oommen N.B., Folkerd E., Messiou C., Molife L.R., Maier G., Thompson E., et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009, 27:3742-3748.
8. Nagrath S., Sequist L.V., Maheswaran S., Bell D.W., Irimia D., Ulkus L., Smith M.R., Kwak E.L., Digumarthy S., Muzikansky A., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450:1235-1239.
9. Alix-Panabières C., Brouillet J.-P., Fabbro M., Yssel H., Rousset T., Maudelonde T., Choquet-Kastylevsky G., Vendrell J.-P. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods 2005, 299:177-188.
10. Krivacic R.T., Ladanyi A., Curry D.N., Hsieh H.B., Kuhn P., Bergsrud D.E., Kepros J.F., Barbera T., Ho M.Y., Chen L.B., et al. A rare-cell detector for cancer. Proc Natl Acad Sci USA 2004, 101:10501-10504.
11. Sieuwerts A.M., Kraan J., Bolt J., van der Spoel P., Elstrodt F., Schutte M., Martens J.W.M., Gratama J.-W., Sleijfer S., Foekens J.A. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009, 101:61-66.
12. Mani S.A., Guo W., Liao M.-J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
13. Connelly M., Wang Y., Doyle G.V., Terstappen L., McCormack R. Re: anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009, 101:896-897. 895; author reply.
14. Tibbe A.G., de Grooth B.G., Greve J., Liberti P.A., Dolan G.J., Terstappen L.W. Optical tracking and detection of immunomagnetically selected and aligned cells. Nat Biotechnol 1999, 17:1210-1213.
15. Racila E., Euhus D., Weiss A.J., Rao C., McConnell J., Terstappen L.W., Uhr J.W. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA 1998, 95:4589-4594.
16. Allard W.J., Matera J., Miller M.C., Repollet M., Connelly M.C., Rao C., Tibbe A.G.J., Uhr J.W., Terstappen L.W.M.M. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897-6904.
17. Miller M.C., Doyle G.V., Terstappen L.W.M.M. Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010, 617421.
18. Swennenhuis J.F., Tibbe A.G.J., Levink R., Sipkema R.C.J., Terstappen L.W.M.M. Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry A 2009, 75:520-527.
19. Attard G., Swennenhuis J.F., Olmos D., Reid A.H.M., Vickers E., A'Hern R., Levink R., Coumans F., Moreira J., Riisnaes R., et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009, 69:2912-2918.
20. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.-W., Varambally S., Cao X., Tchinda J., Kuefer R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
21. Clark J., Attard G., Jhavar S., Flohr P., Reid A., De-Bono J., Eeles R., Scardino P., Cuzick J., Fisher G., et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 2008, 27:1993-2003.
22. Ntouroupi T.G., Ashraf S.Q., McGregor S.B., Turney B.W., Seppo A., Kim Y., Wang X., Kilpatrick M.W., Tsipouras P., Tafas T., et al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer 2008, 99:789-795.
23. Vona G., Sabile A., Louha M., Sitruk V., Romana S., Schütze K., Capron F., Franco D., Pazzagli M., Vekemans M., et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000, 156:57-63.
24. De Giorgi V., Pinzani P., Salvianti F., Panelos J., Paglierani M., Janowska A., Grazzini M., Wechsler J., Orlando C., Santucci M., et al. Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol 2010, 130:2440-2447.
25. Cristofanilli M., Hayes D.F., Budd G.T., Ellis M.J., Stopeck A., Reuben J.M., Doyle G.V., Matera J., Allard W.J., Miller M.C., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23:1420-1430.
26. Olmos D., Arkenau H.-T., Ang J.E., Ledaki I., Attard G., Carden C.P., Reid A.H.M., A'Hern R., Fong P.C., Oomen N.B., et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 2009, 20:27-33.
27. Scher H.I., Jia X., de Bono J.S., Fleisher M., Pienta K.J., Raghavan D., Heller G. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009, 10:233-239.
28. Hou J.-M., Krebs M., Ward T., Morris K., Sloane R., Blackhall F., Dive C. Circulating tumor cells, enumeration and beyond. Cancers 2010, 1-15.
29. Danila D.C., Heller G., Gignac G.A., Gonzalez-Espinoza R., Anand A., Tanaka E., Lilja H., Schwartz L., Larson S., Fleisher M., et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007, 13:7053-7058.
30. Stott S.L., Lee R.J., Nagrath S., Yu M., Miyamoto D.T., Ulkus L., Inserra E.J., Ulman M., Springer S., Nakamura Z., et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010, 2-25 ra23.
31. Punnoose E.A., Atwal S.K., Spoerke J.M., Savage H., Pandita A., Yeh R.-F., Pirzkall A., Fine B.M., Amler L.C., Chen D.S., et al. Molecular biomarker analyses using circulating tumor cells. PLoS ONE 2010, 5. e12517.
32. Pachmann K., Camara O., Kavallaris A., Krauspe S., Malarski N., Gajda M., Kroll T., Jorke C., Hammer U., Altendorf-Hofmann A., et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008, 26:1208-1215.
33. Coumans F.A.W., Doggen C.J.M., Attard G., de Bono J.S., Terstappen L.W.M.M. All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 2010.
34. Meng S., Tripathy D., Shete S., Ashfaq R., Haley B., Perkins S., Beitsch P., Khan A., Euhus D., Osborne C., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004, 101:9393-9398.
35. Riethdorf S., Müller V., Zhang L., Rau T., Loibl S., Komor M., Roller M., Huober J., Fehm T., Schrader I., et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010, 16:2634-2645.
36. Bubendorf L., Kononen J., Koivisto P., Schraml P., Moch H., Gasser T.C., Willi N., Mihatsch M.J., Sauter G., Kallioniemi O.P. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999, 59:803-806.
37. Shaffer D.R., Leversha M.A., Danila D.C., Lin O., Gonzalez-Espinoza R., Gu B., Anand A., Smith K., Maslak P., Doyle G.V., et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007, 13:2023-2029.
38. de Bono J.S., Attard G., Adjei A., Pollak M.N., Fong P.C., Haluska P., Roberts L., Melvin C., Repollet M., Chianese D., et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007, 13:3611-3616.
39. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., Inserra E., Diederichs S., Iafrate A.J., Bell D.W., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.
40. Smirnov D.A., Zweitzig D.R., Foulk B.W., Miller M.C., Doyle G.V., Pienta K.J., Meropol N.J., Weiner L.M., Cohen S.J., Moreno J.G., et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005, 65:4993-4997.
41. Tang F., Barbacioru C., Wang Y., Nordman E., Lee C., Xu N., Wang X., Bodeau J., Tuch B.B., Siddiqui A., et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods 2009, 6:377-382.
42. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
43. Schwarzenbach H., Alix-Panabières C., Müller I., Letang N., Vendrell J.-P., Rebillard X., Pantel K. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009, 15:1032-1038.
44. Liu W., Laitinen S., Khan S., Vihinen M., Kowalski J., Yu G., Chen L., Ewing C.M., Eisenberger M.A., Carducci M.A., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009, 15:559-565.